Gilead Sciences, Inc.  

(Public, NASDAQ:GILD)   Watch this stock  
Find more results for GILD
79.40
-1.29 (-1.60%)
After Hours: 79.70 +0.30 (0.38%)
Feb 22, 4:53PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 79.18 - 81.13
52 week 63.76 - 89.54
Open 80.73
Vol / Avg. 8.38M/10.15M
Mkt cap 103.69B
P/E 10.33
Div/yield 0.57/2.87
EPS 7.68
Shares 1.31B
Beta 1.22
Inst. own 81%
May 10, 2018
Gilead Sciences Inc Annual Shareholders Meeting (Estimated) - 1:00PM EDT - Add to calendar
Apr 30, 2018
Q1 2018 Gilead Sciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 21, 2018
Gilead Sciences Inc at RBC Capital Markets Healthcare Conference - Webcast
Feb 6, 2018
Q4 2017 Gilead Sciences Inc Earnings Call - Webcast
Feb 6, 2018
Q4 2017 Gilead Sciences Inc Earnings Release
Jan 8, 2018
Gilead Sciences Inc at JPMorgan Healthcare Conference - Webcast
Dec 6, 2017
Gilead Sciences Inc at Nasdaq Investor Program - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 27.80% 38.82%
Operating margin 38.51% 54.10%
EBITD margin - 58.85%
Return on average assets 9.83% 15.93%
Return on average equity 28.75% 51.38%
Employees 9,000 -
CDP Score - -

Address

333 LAKESIDE DR
FOSTER CITY, CA 94404
United States - Map
+1-650-5743000 (Phone)
+1-650-5789264 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Officers and directors

John C. Martin Ph.D. Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
John F. Milligan Ph.D. President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Robin L. Washington Chief Financial Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Kevin B. Young Chief Operating Officer
Age: 59
Bio & Compensation  - Reuters
Norbert W. Bischofberger Ph.D. Executive Vice President - Research and Development, Chief Scientific Officer
Age: 61
Bio & Compensation  - Reuters
Gregg H. Alton Executive Vice President - Corporate and Medical Affairs
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
James R. Meyers Executive Vice President - Worldwide Commercial Operations
Age: 52
Bio & Compensation  - Reuters
John F. Cogan Jr. Ph.D. Lead Independent Director
Age: 69
Bio & Compensation  - Reuters
Jacqueline K. Barton Director
Age: 64
Bio & Compensation  - Reuters
Kelly A. Kramer Independent Director
Age: 49
Bio & Compensation  - Reuters